Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study
Arjun Vasant Balar(NYU Langone Health), Ashish M. Kamat(The University of Texas MD Anderson Cancer Center), Girish S. Kulkarni(University Health Network), Edward Uchio(University of California, Irvine), Joost L. Boormans(Erasmus MC), M. Roumiguié(Institut universitaire du cancer de Toulouse Oncopole), Laurence E. Krieger(Royal North Shore Hospital), Eric A. Singer(Rutgers Cancer Institute of New Jersey), Dean F. Bajorin(Memorial Sloan Kettering Cancer Center), Petros Grivas(University of Washington), Ho Kyung Seo(National Cancer Center), Hiroyuki Nishiyama(University of Tsukuba), Badrinath R. Konety(University of Minnesota), Haojie Li(Merck & Co., Inc., Rahway, NJ, USA (United States)), Kijoeng Nam(Merck & Co., Inc., Rahway, NJ, USA (United States)), Ekta Kapadia(Merck & Co., Inc., Rahway, NJ, USA (United States)), Tara L. Frenkl(Merck & Co., Inc., Rahway, NJ, USA (United States)), Ronald de Wit(Erasmus MC Cancer Institute)
Cited by 530
Abstract
Related Papers
No related papers found
Powered by citation graph analysis